The chief executives of some of America’s largest health insurers are set to face pointed questions from lawmakers this week as Washington intensifies its scrutiny of rising health care costs, insurance premiums, and the role insurers play in shaping what Americans ultimately pay for coverage and prescription drugs.
Executives from UnitedHealth Group, CVS Health, Cigna Group, Humana, and Elevance Health are scheduled to testify before a House Energy and Commerce subcommittee in the morning, followed by an appearance before the House Ways and Means Committee later in the day. The hearings come at a politically sensitive moment, with affordability becoming a dominant issue ahead of the midterm election cycle and voters increasingly frustrated with health care expenses that continue to outpace wage growth.
The companies represented collectively insure tens of millions of Americans through employer plans, Medicare Advantage programs for seniors, and individual marketplace coverage. They also operate some of the largest pharmacy benefit managers in the country, which negotiate drug prices, manage formularies, and administer prescription benefits for employers and government programs.
Why Lawmakers Are Turning Up the Heat
Health care spending in the United States reached approximately $5.3 trillion in 2024, reflecting a 7.2 percent increase from the prior year based on recent government estimates. That figure represents nearly one fifth of the entire U.S. economy, underscoring how deeply medical costs affect household budgets, employer benefit decisions, and federal spending.
Members of Congress from both parties have signaled growing concern that consumers are absorbing too much of the cost burden, particularly through higher insurance premiums, deductibles, and pharmacy expenses. While hospitals, drugmakers, and physician networks drive a large share of total spending, insurers serve as the financial gatekeepers of the system, which makes them an easy political target when affordability becomes a campaign issue.
In prepared testimony submitted ahead of the hearings, insurance executives are expected to emphasize that premiums reflect the underlying cost of medical services and prescription drugs. They also highlight efforts to negotiate lower prices, expand preventive care, and manage utilization to slow overall spending growth.
Lawmakers, however, are likely to press executives on how much pricing power insurers exert through their pharmacy benefit operations, whether administrative costs and profit margins contribute to premium increases, and how denial rates affect patient access to care.
Market Performance Adds Investor Pressure
Investors are watching the hearings closely as regulatory scrutiny often translates into policy risk for large managed care companies.
UnitedHealth Group shares are up roughly 3 percent so far this year, reflecting steady enrollment growth and strong performance from its Optum health services division. CVS Health has gained about 1 to 2 percent year to date as the company continues integrating its Aetna insurance arm and expanding primary care services through Oak Street Health and MinuteClinic. Cigna shares have lagged slightly, posting a modest decline, as investors weigh slower growth in certain commercial segments and continued uncertainty around pharmacy benefit margins.
By comparison, the broader S&P 500 index has posted modest gains during the same period.
All three companies are expected to report earnings in the coming weeks, making the congressional hearings a potential source of headline risk if lawmakers signal forthcoming legislation or regulatory changes.
Expiring Subsidies Are Driving Premium Anxiety
One of the most immediate drivers of public concern is the expiration of enhanced government subsidies for health plans purchased through the Affordable Care Act marketplaces. Those subsidies were expanded during the pandemic and helped millions of households afford individual coverage.
With several of those provisions expiring in 2025, many consumers are now facing sharply higher monthly premiums. Estimates from health policy researchers suggest that average premiums could more than double for some households without renewed subsidies.
The issue has already spilled into political gridlock. A partisan dispute over whether to extend the subsidies contributed to a lengthy government shutdown last fall, reinforcing how deeply health care affordability has become entangled with fiscal politics.
For insurers, subsidy uncertainty complicates pricing models and enrollment forecasts. If subsidies lapse permanently, healthier consumers may drop coverage, raising risk pools and driving premiums even higher in future years. That dynamic is something lawmakers will likely probe during the hearings.
Pharmacy Benefit Managers Under Renewed Scrutiny
Another focal point of the hearings will be pharmacy benefit managers, or PBMs, which sit at the center of prescription drug pricing negotiations. UnitedHealth operates Optum Rx, CVS controls Caremark, and Cigna owns Express Scripts.
PBMs negotiate rebates with drug manufacturers, determine which medications are covered, and influence what patients pay at the pharmacy counter. Critics argue that opaque rebate structures distort pricing incentives and may inflate list prices. Supporters counter that PBMs extract significant discounts that ultimately reduce overall drug spending.
Both parties in Congress have floated legislation aimed at increasing transparency, limiting spread pricing practices, and restructuring rebate flows. Any meaningful reform could materially impact revenue models for the large insurers that rely on PBM scale as a profit driver.
Trump’s Health Plan Adds Political Momentum
President Donald Trump recently introduced what the administration calls the Great Healthcare Plan, a proposal aimed at reducing prescription drug costs and insurance premiums while increasing consumer transparency.
Among its provisions, the plan would redirect subsidy payments directly to consumers rather than insurers, giving individuals more flexibility in choosing coverage. It also would require insurers to “publish the percentage of insurance claims they reject” on their websites, a measure intended to increase accountability and public awareness of claim approval practices.
The proposal is expected to face resistance in Congress, particularly around funding mechanisms and regulatory authority. Still, the announcement adds political momentum to the broader affordability debate and raises the possibility of additional regulatory pressure on insurers.
How Insurers Are Likely to Defend Their Position
Executives are expected to argue that insurers operate on relatively thin margins compared with hospitals and pharmaceutical companies. They may also emphasize investments in value based care models, preventive health programs, digital health tools, and home based care services designed to reduce long term costs.
UnitedHealth, for example, has increasingly positioned itself as a diversified health services company rather than simply an insurer, with Optum providing analytics, pharmacy services, and physician networks. CVS has leaned into vertical integration across insurance, retail pharmacy, and primary care. Cigna continues expanding specialty pharmacy and employer focused health solutions.
Executives will likely frame these strategies as part of a broader effort to modernize the health system and improve efficiency rather than inflate profits.
What This Means for Investors
For investors, the hearings reinforce a long running reality. Large health insurers operate in a politically sensitive sector where regulatory risk never fully disappears.
Key factors to watch include:
- Potential legislation affecting pharmacy benefit transparency or rebate structures
- Changes to ACA subsidy policy and enrollment dynamics
- Increased reporting requirements around claims approvals and denials
- Margin pressure from pricing regulation or administrative mandates
- Continued consolidation or vertical integration strategies
Despite political noise, the sector has historically demonstrated resilience due to recurring revenue, aging demographics, and steady demand for medical coverage. Medicare Advantage enrollment continues to grow as baby boomers age into eligibility, providing long term tailwinds for major insurers.
However, heightened scrutiny can compress valuation multiples if investors anticipate tighter regulation or slower profit growth. Short term volatility around hearings and policy announcements is common, particularly when election cycles intensify.
Bottom Line
The upcoming congressional hearings place UnitedHealth, CVS, Cigna, and their peers squarely in the political spotlight as lawmakers seek answers on why health care costs remain stubbornly high for American families.
While insurers will argue that broader system costs drive premium increases, the public and policymakers increasingly expect more transparency, accountability, and affordability from the companies managing coverage for tens of millions of Americans.
For investors, the hearings serve as a reminder that regulatory risk remains a core variable in the health insurance sector. Monitoring policy developments alongside earnings performance will be essential as Washington debates the future of subsidies, pharmacy pricing, and consumer protections in the year ahead.
About Author
